Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 4

Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

The University of Texas Medical Branch, Galveston · with Cancer Prevention Research Institute of Texas · NCT05672927

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 27–45 · Women only
Healthy volunteers
Accepted
Study type
Interventional · Phase 4
Target enrollment
618
US sites recruiting
1
Study start
January 18, 2023
Record last updated
September 15, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood draw,12 months after their initial vaccination.

Being studied: 9-valent HPV vaccine, 2 doses alternate timing; 9-valent HPV vaccine, 3 doses standard timing

Conditions: Immunization; HPV Infection; Human Papillomavirus

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion criteria

  • Females 27-45 years old.
  • Ability to give informed consent.
  • Has not received any prior doses of the HPV vaccine. This will be verified by the person and state registry (Immtrac), as well as the person's electronic medical record.
  • Reliable telephone access for the duration of the project.
  • Can read and speak in either English or Spanish.
  • Identified source of funding for vaccine such as Medicaid, private health insurance, Texas Healthy Women program, etc.
  • Reports consistent use of reliable birth control and plans to continue its use through study month 13.

Exclusion criteria

  • Currently pregnant or plans to become pregnant or donate eggs in the next 13 months. Any subjects with positive pregnancy tests at the initial visit will be disqualified from the study and advised to seek prenatal care.
  • Has an immunodeficiency or autoimmune disease such as HIV infection, lymphoma, leukemia, lupus, rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition.
  • Currently receiving treatment or medication that can suppress immune function including radiation therapy, chemotherapy, cyclosporin, leflunomide (Arava), TNF-α antagonists, monoclonal antibody therapies (including rituximab [Rituxan]), intravenous gamma globulin (IVIG), antilymphocyte sera, other therapy known to interfere with the immune response, or systemic corticosteroids (by mouth or intramuscular injection). Those using or have used steroids that are inhaled, placed in the eye, applied on the skin, or injected into the joint/soft tissue will be considered eligible for the study.
  • History of splenectomy
  • Known allergies to any vaccine components, including aluminum, yeast or Benzonase.
  • Febrile at ≥100°F in the 24 hours prior to vaccination. The patients may be rescheduled for a later date.
  • History of thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
  • History of >10 sexual partners in their lifetime at time of enrollment
  • Plans to move out of the Galveston/Houston area in the 13 months following study entry.

Recruiting US locations

  • University of Texas Medical Branch

    Galveston, TX 77555

    Site contact: Rosalina M Trujillo · 409-747-5594 · rmtrujil@UTMB.EDU

Study contacts (from the official record)

  • Abbey B Berenson, MD, PhD · 409-772-2417 · abberens@utmb.edu
  • Rosalina M Trujillo · 409-747-5594 · rmtrujil@utmb.edu
All vaccine studies in Texas →
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old) (NCT05672927) | Bored Studies